Insight Brief: Real-World Evidence & Alzheimer’s Disease
Friday, July 7, 2023
The recent regulatory decisions for Alzheimer’s disease therapies – including traditional approval for LEQEMBI – are exciting developments but also bring additional requirements from payers. Understanding complex stakeholder requirements and applying them to your real-world evidence strategy early in development is critical to accelerating access for your Alzheimer’s treatment.
Download our complimentary insight brief “Real-World Evidence is Front-and-Center in Alzheimer’s Disease” to understand the evolving landscape and how to start planning for post-marketing requirements in this space.
In this brief, you’ll get full details on:
- FDA’s Accelerated Approval Pathway support of Alzheimer’s treatments
- Recent drug development and real-world evidence requirements
- How to align your real-world evidence strategy and operational approach
Use the form below to access the insights from Executive Director, Real-World Evidence Study Solutions Judy Lytle.